1. Home
  2. SLG vs LQDA Comparison

SLG vs LQDA Comparison

Compare SLG & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SL Green Realty Corp

SLG

SL Green Realty Corp

N/A

Current Price

$49.15

Market Cap

3.5B

Sector

Real Estate

ML Signal

N/A

LQDA

Liquidia Corporation

N/A

Current Price

$57.57

Market Cap

4.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SLG
LQDA
Founded
1980
2004
Country
United States
United States
Employees
1289
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
4.0B
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
SLG
LQDA
Price
$49.15
$57.57
Analyst Decision
Hold
Buy
Analyst Count
17
8
Target Price
$55.65
★ $63.88
AVG Volume (30 Days)
1.0M
★ 3.1M
Earning Date
10-21-2026
11-10-2026
Dividend Yield
★ 5.07%
N/A
EPS Growth
N/A
★ 51.81
EPS
★ N/A
N/A
Revenue
★ $1,003,046,000.00
$158,320,000.00
Revenue This Year
N/A
$379.72
Revenue Next Year
N/A
$17.90
P/E Ratio
N/A
★ N/A
Revenue Growth
13.18
★ 1031.18
52 Week Low
$34.77
$22.31
52 Week High
$60.09
$93.61

Technical Indicators

Market Signals
Indicator
SLG
LQDA
Relative Strength Index (RSI) 46.63 67.76
Support Level $48.65 $53.06
Resistance Level $49.71 $63.46
Average True Range (ATR) 1.83 3.42
MACD -0.08 2.35
Stochastic Oscillator 11.98 91.35

Price Performance

Historical Comparison
SLG
LQDA

About SLG SL Green Realty Corp

SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 30.6 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: